Last edition
News about "Arrowhead Pharmaceuticals "
Arrowhead and Novartis Sign Global License and Collaboration Deal
Novartis secures exclusive global rights to Arrowhead’s ARO-SNCA therapy for Parkinson’s and related disorders, with Arrowhead receiving USD 200 million upfront.
Arrowhead Pharmaceuticals | 05/09/2025 | By Dineshwori
Arrowhead Pharmaceuticals Expands its New Patient-Centric Resources for FCS Patients
This new phase introduces a dedicated educational website, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS).
Arrowhead Pharmaceuticals | 03/03/2025 | By Aishwarya | 146
Arrowhead Pharmaceuticals Secures FDA Breakthrough Therapy Designation for Plozasiran
Arrowhead intends to submit a New Drug Application to the FDA by year-end 2024 and plans to seek regulatory approval with additional global regulatory authorities thereafter.
Arrowhead Pharmaceuticals | 13/09/2024 | By Aishwarya | 393
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy